VPS26B Antibody

What is VPS26B and what is its primary function in cellular processes?

VPS26B is a component of the retromer cargo-selective complex (CSC) that plays a critical role in preventing missorting of transmembrane cargo proteins into lysosomal degradation pathways. The protein acts as part of various retromer complex variants, including the SNX-BAR retromer, which mediates retrograde transport from endosomes to the trans-Golgi network (TGN), and the SNX27-retromer, which facilitates endosome-to-plasma membrane trafficking and recycling of cargo proteins . Structurally, VPS26B consists of two curved β-sandwich domains connected by a polar core and a flexible linker, with an unexpected structural relationship to arrestins . In cellular function, VPS26B is predicted to be involved in intracellular protein transport and retrograde transport from endosome to Golgi, as well as acting upstream within cellular responses to type II interferon .

How should VPS26B antibodies be stored and handled for optimal performance?

For optimal antibody performance, store VPS26B antibodies at -20°C for long-term storage (up to 12 months from receipt date) in their original supplied condition. After reconstitution, the antibody can be stored at 2-8°C for up to 6 months . It's critical to avoid repeated freeze-thaw cycles as this significantly degrades antibody quality and performance. Commercial preparations typically contain stabilizers such as glycerol (50%), BSA (1 mg), and preservatives like sodium azide (0.02% NaN3) in PBS buffer . When handling the antibody, maintain sterile conditions and use proper pipetting techniques to prevent contamination that could affect experimental results. Allow antibodies to equilibrate to room temperature before opening vials to prevent condensation that could introduce contaminants.

What applications are VPS26B antibodies suitable for in research settings?

VPS26B antibodies have been validated for multiple research applications, providing versatility for investigating protein localization, expression, and interactions. The antibodies are typically guaranteed for Western blotting (WB), immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA) . When using VPS26B antibodies for immunohistochemistry on paraffin-embedded tissues (IHC-P), researchers should optimize antigen retrieval methods to ensure proper epitope exposure . For immunofluorescence studies, these antibodies can help visualize the endosomal localization of VPS26B and its colocalization with other retromer components such as SNX1 . The multi-application capability of these antibodies makes them valuable tools for comprehensive protein characterization across different experimental platforms.

What controls should be included when using VPS26B antibodies for immunofluorescence studies?

When conducting immunofluorescence studies with VPS26B antibodies, several controls are essential for reliable data interpretation:

• Positive Controls: Include cells or tissues known to express VPS26B. For example, using cell lines with verified endosomal localization of the retromer complex components.

• Negative Controls: Utilize samples where primary antibody is omitted but secondary antibody is applied to assess non-specific binding.

• Specificity Controls: Include cells where VPS26B expression has been knocked down or knocked out via siRNA or CRISPR to confirm signal specificity.

• Colocalization Controls: As VPS26B functions as part of the retromer complex, co-staining with other retromer components such as SNX1 or VPS35 provides validation of proper localization . Research has established that wild-type VPS26 constructs colocalize with endogenous SNX1 on endosomes, while mutated constructs (particularly those with alterations in the Vps35-binding site) show diffuse cytosolic distribution .

• Isotype Controls: Include an irrelevant antibody of the same isotype, host species, and concentration to identify potential non-specific binding.

These controls collectively ensure that observed signals represent true VPS26B localization rather than artifacts or non-specific binding.

How can researchers optimize Western blot protocols for VPS26B detection?

Optimizing Western blot protocols for detecting VPS26B (calculated molecular weight: 39.125 kDa ) requires attention to several key parameters:

• Sample Preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if investigating phosphorylation states

  • Determine optimal protein loading amount (typically 20-40 μg total protein)

• Gel Selection and Transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Select PVDF membranes for higher protein binding capacity

  • Optimize transfer conditions: 100V for 1 hour or 30V overnight at 4°C

• Antibody Dilution and Incubation:

  • Test different dilutions of primary antibody (typically starting at 1:500-1:1000)

  • Incubate primary antibody overnight at 4°C to maximize specific binding

  • Use 5% non-fat dry milk or BSA in TBST for blocking and antibody dilution

• Detection System:

  • Choose enhanced chemiluminescence (ECL) systems appropriate for expected expression levels

  • Consider fluorescence-based detection for more precise quantification

• Controls:

  • Include positive control lysates from cells known to express VPS26B

  • Use loading controls like GAPDH or β-actin for normalization

  • Consider using VPS26B knockdown/knockout samples as negative controls

Researchers should verify the specificity of bands by comparing to the predicted molecular weight (39.125 kDa) and validating with appropriate positive and negative controls.

What is the recommended protocol for immunoprecipitation (IP) using VPS26B antibodies?

A robust immunoprecipitation protocol for VPS26B should include the following steps:

• Cell Lysis:

  • Harvest cells (1-2 × 10^7) and wash twice with ice-cold PBS

  • Lyse cells in 1 mL IP lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, plus protease inhibitors)

  • Incubate on ice for 30 minutes with occasional mixing

  • Centrifuge at 14,000g for 15 minutes at 4°C and collect supernatant

• Pre-clearing (optional but recommended):

  • Add 50 μL of Protein A/G beads to lysate

  • Incubate for 1 hour at 4°C with gentle rotation

  • Remove beads by centrifugation at 1,000g for 5 minutes

• Antibody Binding:

  • Add 2-5 μg of VPS26B antibody to pre-cleared lysate

  • Incubate overnight at 4°C with gentle rotation

• Immunoprecipitation:

  • Add 50 μL of Protein A/G beads to the lysate-antibody mixture

  • Incubate for 2-4 hours at 4°C with gentle rotation

  • Collect beads by centrifugation at 1,000g for 5 minutes

  • Wash beads 4-5 times with washing buffer (lysis buffer with reduced detergent concentration)

• Elution and Analysis:

  • Elute proteins by boiling beads in SDS sample buffer

  • Analyze by SDS-PAGE and Western blotting

This protocol has been successfully used to demonstrate the interaction of VPS26 with other retromer components, including VPS35 and VPS29 . When wild-type VPS26 was immunoprecipitated, it co-precipitated endogenous VPS35 and VPS29, while mutant forms with alterations in the VPS35-binding loop failed to co-precipitate these proteins .

How can researchers effectively study the interaction between VPS26B and VPS35 using antibody-based techniques?

Studying the VPS26B-VPS35 interaction requires strategic experimental design, as this interaction is critical for retromer complex assembly and function. The binding interface has been mapped to a mobile loop spanning residues 235-246 near the tip of the C-terminal domain of VPS26 .

Recommended Methodological Approach:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate VPS26B using anti-VPS26B antibodies

  • Detect co-precipitated VPS35 by Western blotting

  • Include controls with VPS26B mutants affecting the binding loop (I235D M236D or Δ238-246 GG mutations), which should show reduced or abolished VPS35 binding

• Proximity Ligation Assay (PLA):

  • Use anti-VPS26B and anti-VPS35 antibodies from different species

  • Apply species-specific secondary antibodies with attached DNA probes

  • Quantify interaction signals through fluorescent detection of amplified DNA

• FRET or BRET Analysis:

  • Create fluorescent or bioluminescent fusion proteins with VPS26B and VPS35

  • Measure energy transfer as indication of protein proximity

  • Compare wild-type proteins to binding site mutants

• Structure-Function Analysis:

  • Introduce targeted mutations in the VPS35-binding loop of VPS26B

  • Test the effects on protein interaction, complex assembly, and cellular localization

  • Based on published research, mutations like I235D M236D completely abrogate interaction with VPS35, while alterations like G238P show interaction under low stringency conditions but fail under high stringency conditions

Research has demonstrated that mutations in this binding loop not only disrupt the VPS26-VPS35 interaction but also prevent the recruitment of VPS26 to endosomes, highlighting the functional importance of this interaction for proper retromer assembly and localization .

What are the implications of VPS26B mutations for retromer complex function and human disease?

VPS26B mutations have significant implications for retromer complex assembly, cellular trafficking, and potential disease mechanisms:

Retromer Assembly and Function:
Mutations in the VPS35-binding loop of VPS26B (residues 235-246) prevent proper assembly with VPS35 and VPS29, thereby disrupting the formation of the cargo-selective complex (CSC) . Research has demonstrated that mutations like I235D M236D and Δ238-246 GG completely abolish interaction with VPS35 and prevent endosomal localization of VPS26B . In yeast, analogous mutations lead to defects in carboxypeptidase Y (CPY) processing and sorting, indicating functional impairment of the retromer complex .

Trafficking Pathways Affected:
VPS26B mutations can disrupt multiple trafficking pathways:

• Retrograde transport from endosomes to trans-Golgi network (TGN)

• Endosome-to-plasma membrane recycling

• Prevention of lysosomal degradation of transmembrane cargo proteins

• SNX27-mediated endocytic recycling of metabolic transporters like SLC2A1/GLUT1

Disease Implications:
Though direct VPS26B mutations have not been extensively linked to specific diseases, disruptions in retromer function have been implicated in:

• Neurodegenerative disorders (particularly Alzheimer's and Parkinson's diseases)

• Developmental disorders

• Metabolic dysfunctions due to misrouting of transporters

• Potential inflammatory pathways, as VPS26B is predicted to act within cellular responses to type II interferon

Understanding these pathways provides avenues for therapeutic interventions targeting retromer function or bypassing trafficking defects caused by VPS26B mutations.

How can researchers differentiate between VPS26A and VPS26B paralogs in their experiments?

Differentiating between VPS26A and VPS26B paralogs is crucial for understanding their specific roles in retromer function. These methodological approaches ensure accurate paralog-specific analysis:

Antibody Selection and Validation:

• Use antibodies raised against unique epitopes of each paralog

• Validate antibody specificity using overexpression and knockdown controls

• Confirm specificity by testing on tissues from knockout models of each paralog

Expression Analysis Techniques:

• RT-qPCR:

  • Design primers targeting non-homologous regions

  • Validate primer specificity using plasmids containing each paralog

  • Include melt curve analysis to confirm amplicon specificity

• Western Blotting:

  • Exploit slight differences in molecular weight (VPS26A: 38.2 kDa; VPS26B: 39.1 kDa)

  • Use high-resolution gels (10-12%) for better separation

  • Include positive controls expressing only one paralog

• Immunofluorescence:

  • Use validated paralog-specific antibodies

  • Include co-staining with markers of distinct retromer complexes

  • Analyze colocalization patterns, as VPS26A and VPS26B may localize to different subcellular compartments

Functional Differentiation:

• VPS26A and VPS26B have some redundant functions but also distinct roles

• VPS26B appears to act redundantly with VPS26A in SNX27-mediated endocytic recycling of SLC2A1/GLUT1

• VPS26B may be involved in retrograde transport of SORT1 but not IGF2R

These approaches enable researchers to accurately differentiate between the paralogs and understand their specific contributions to retromer function and cellular trafficking.

What are common issues in VPS26B antibody-based experiments and how can they be resolved?

Researchers commonly encounter several challenges when working with VPS26B antibodies. Here are the most frequent issues and their solutions:

When troubleshooting, it's critical to include appropriate positive and negative controls. Research has shown that wild-type VPS26 localizes to endosomes and co-precipitates with VPS35/VPS29, while mutations in the 235-246 loop region result in diffuse cytoplasmic distribution and failure to integrate into the retromer complex .

How should researchers interpret data from VPS26B co-localization studies with other retromer components?

Interpreting co-localization studies between VPS26B and other retromer components requires careful analysis and consideration of several factors:

Key Metrics for Quantitative Analysis:

• Pearson's correlation coefficient (values >0.6 indicate significant co-localization)

• Manders' overlap coefficient (measures proportion of overlap between signals)

• Object-based co-localization (counts distinct punctate structures containing both proteins)

Expected Patterns and Their Interpretation:

• Strong co-localization with VPS35 and VPS29: Indicates proper assembly of the cargo-selective complex (CSC) of retromer . This pattern is expected for wild-type VPS26B.

• Partial co-localization with SNX1/SNX2: Suggests assembly of the SNX-BAR retromer variant involved in endosome-to-TGN transport . The degree of overlap may vary depending on cellular conditions.

• Co-localization with SNX27: Indicates formation of the SNX27-retromer complex involved in endosome-to-plasma membrane recycling .

• Diffuse cytosolic pattern without punctate structures: When VPS26B fails to co-localize with other retromer components, particularly when the protein shows a diffuse cytosolic pattern rather than distinct endosomal localization, this suggests failure to incorporate into the retromer complex. This pattern is observed with mutations in the VPS35-binding loop (residues 235-246) .

• Co-localization with endosomal markers: VPS26B should show partial co-localization with early endosomal markers (e.g., EEA1) and late endosomal markers (e.g., Rab7), consistent with its function in various endosomal compartments .

Research has demonstrated that wild-type VPS26 co-localizes with SNX1 on endosomes, while mutants with disrupted VPS35 binding show diffuse cytosolic distribution . This visual evidence complements biochemical data on complex assembly and provides crucial information about the functional status of VPS26B in the retromer system.

What considerations are important when analyzing VPS26B expression levels in different tissues or cell types?

When analyzing VPS26B expression across tissues or cell types, researchers should consider several critical factors to ensure reliable and meaningful interpretation:

Normalization and Reference Controls:

• Use multiple housekeeping genes for normalization (GAPDH, β-actin, and HPRT)

• Include tissue-specific reference genes when comparing across different tissues

• Consider using relative quantification with a reference tissue/cell type

Technical Considerations:

• Antibody Validation: Confirm antibody specificity in each tissue/cell type, as background and cross-reactivity can vary across different cellular contexts.

• VPS26A vs. VPS26B: Always verify you're detecting the intended paralog, as VPS26A and VPS26B have high sequence similarity but potentially different expression patterns.

• Extraction Methods: Different tissues may require modified protein extraction protocols to ensure complete solubilization of membrane-associated proteins like VPS26B.

Biological Interpretation Factors:

• Functional Context: VPS26B expression should be analyzed in the context of other retromer components (VPS35, VPS29, sorting nexins) to understand the complete functional unit.

• Subcellular Localization: Beyond total expression levels, the proportion of VPS26B that localizes to endosomes versus cytosol can provide insights into functional integration into retromer complexes.

• Physiological State: Expression and localization may change with cellular stress, differentiation state, or disease progression.

• Splice Variants: Consider potential tissue-specific splice variants that might not be detected by all antibodies.

• Post-translational Modifications: These modifications might affect antibody recognition and provide insights into regulatory mechanisms.

When reporting expression data, include detailed methodological information and acknowledge these potential variables to ensure appropriate interpretation of tissue or cell-type specific differences in VPS26B expression.

What novel techniques could enhance the study of VPS26B dynamics and interactions in living cells?

Emerging technologies offer exciting opportunities for studying VPS26B dynamics and interactions with unprecedented resolution and in real-time:

Advanced Imaging Approaches:

• Live-cell Super-resolution Microscopy: Techniques like PALM, STORM, or STED microscopy can visualize VPS26B-containing retromer complexes at nanoscale resolution, revealing structural organization beyond the diffraction limit. This could illuminate the spatial arrangement of VPS26B relative to other retromer components during vesicle formation.

• Lattice Light-sheet Microscopy: This technique enables long-term 3D imaging with minimal phototoxicity, ideal for tracking VPS26B-containing vesicle dynamics across the entire cell volume over extended periods.

• Single-particle Tracking: Using photoactivatable or photoconvertible VPS26B fusion proteins to track individual molecules can reveal diffusion rates, binding kinetics, and residence times on endosomal membranes.

Protein Interaction and Modification Technologies:

• Proximity-dependent Labeling: BioID or APEX2 fused to VPS26B can identify transient or weak interaction partners through proximity-dependent biotinylation, potentially revealing novel components of the retromer machinery.

• Optogenetic Tools: Light-inducible dimerization systems fused to VPS26B could allow temporal control of retromer assembly or localization, providing insights into assembly kinetics and functional consequences.

• CRISPR-based Imaging: CRISPR-Cas systems adapted for live-cell RNA imaging could track VPS26B mRNA localization and translation dynamics, revealing spatial regulation of retromer component synthesis.

• Mass Spectrometry Approaches: Combining IP with VPS26B antibodies and quantitative proteomics could identify post-translational modifications and how they change under different conditions, potentially revealing regulatory mechanisms.

These advanced techniques would significantly expand our understanding of VPS26B beyond the static structural information currently available from crystallography studies and provide dynamic insights into retromer assembly, cargo recognition, and trafficking in living cells.

How might targeting VPS26B function have therapeutic potential in diseases related to retromer dysfunction?

Targeting VPS26B function represents a promising avenue for therapeutic intervention in diseases associated with retromer dysfunction:

Therapeutic Approaches:

• Small Molecule Stabilizers: Compounds designed to stabilize the interaction between VPS26B and VPS35 could enhance retromer assembly and function. This approach would be particularly relevant where retromer function is compromised but not completely absent.

• Peptide-based Therapeutics: Synthetic peptides mimicking the VPS35-binding loop of VPS26B (residues 235-246) could be developed to either enhance or competitively inhibit retromer assembly, depending on the therapeutic goal.

• Gene Therapy: Viral vector-mediated delivery of functional VPS26B could restore retromer function in cases where mutations or reduced expression contribute to disease.

• RNA Therapeutics: Antisense oligonucleotides or siRNAs could be used to modulate VPS26B expression or correct splicing defects in specific tissues.

Disease Applications:

• Neurodegenerative Disorders: Enhancing retromer function through VPS26B stabilization could improve trafficking of critical neuronal proteins and reduce toxic protein accumulation in Alzheimer's or Parkinson's disease.

• Metabolic Disorders: Given VPS26B's role in SNX27-mediated recycling of glucose transporters like SLC2A1/GLUT1 , targeting this function could improve metabolic regulation.

• Infectious Diseases: As VPS26B is predicted to be involved in cellular responses to type II interferon , modulating its function could enhance immune responses to certain pathogens.

• Cancer: Appropriate trafficking of growth factor receptors and adhesion molecules is often dysregulated in cancer, making retromer a potential therapeutic target.

Challenges and Considerations:

• Paralog specificity: Therapeutics would need to distinguish between VPS26A and VPS26B

• Tissue-specific delivery: Retromer functions in all cells, requiring targeted delivery to affected tissues

• Complex redundancy: Alternative trafficking pathways might compensate for retromer modulation

Strategic targeting of VPS26B represents a promising approach to modulating retromer function in diverse disease contexts, with the potential to address underlying trafficking defects rather than merely treating symptoms.

What is the current understanding of VPS26B's role in specialized cell types, and what research questions remain unexplored?

The specialized functions of VPS26B in different cell types represent an emerging area of research with significant knowledge gaps:

Current Understanding by Cell Type:

• Neurons:

  • VPS26B likely contributes to specialized trafficking in neuronal compartments

  • Predicted to function at glutamatergic synapses and in postsynaptic endosomal recycling

  • May play roles in neurodevelopment and synaptic plasticity through receptor trafficking

• Immune Cells:

  • Predicted to act upstream of or within cellular responses to type II interferon

  • Potentially involved in cytokine receptor trafficking and immune signaling

• Epithelial Cells:

  • Contributes to polarized trafficking pathways

  • Works with SNX-BAR retromer for endosome-to-TGN transport and SNX27-retromer for endosome-to-plasma membrane recycling

Critical Unanswered Research Questions:

• Paralog-Specific Functions:

  • How do the roles of VPS26A and VPS26B differ in specialized cell types?

  • Do certain tissues or developmental stages preferentially utilize one paralog over the other?

  • What are the functional consequences of VPS26B knockout in specific tissues?

• Regulatory Mechanisms:

  • How is VPS26B expression and function regulated during development and in response to cellular stress?

  • What post-translational modifications occur on VPS26B and how do they affect its function?

  • Do specialized cell types have unique regulatory mechanisms for VPS26B?

• Disease Relevance:

  • How do alterations in VPS26B contribute to tissue-specific pathologies?

  • Does VPS26B play unique roles in specialized cells that are particularly relevant to disease?

  • Can VPS26B function be modulated in a cell-type specific manner for therapeutic purposes?

• Functional Partnerships:

  • Does VPS26B interact with cell-type specific partners beyond the core retromer components?

  • How does the VPS26B-containing retromer coordinate with other trafficking machineries in specialized cells?

• Evolutionary Considerations:

  • Why has VPS26 undergone gene duplication to produce paralogs in vertebrates?

  • Do these paralogs serve fundamentally different functions in complex organisms?

Addressing these questions will require tissue-specific genetic models, advanced imaging in specialized cells, and biochemical approaches to identify cell-type specific interactions. This research could reveal unexpected functions of VPS26B beyond its canonical role in retromer trafficking.

How can researchers integrate findings about VPS26B structure and function to advance understanding of membrane trafficking systems?

Integrating knowledge about VPS26B structure and function provides a foundation for a more comprehensive understanding of membrane trafficking systems. The arrestin-like fold of VPS26B combined with its role in various retromer complexes offers unique perspectives for advancing trafficking research:

Multidisciplinary Integration Approaches:

• Structure-Function Correlation: The resolved crystal structure of VPS26 showing two curved β-sandwich domains connected by a polar core and flexible linker provides a framework for understanding how specific structural elements contribute to function. Researchers should systematically connect structural features to functional outcomes through targeted mutagenesis and functional assays.

• Systems Biology Perspective: VPS26B should be studied not in isolation but as part of an integrated trafficking network. Computational modeling of retromer assembly and function, incorporating known binding interfaces (such as the VPS35-binding loop at residues 235-246) , can predict system-level responses to perturbations.

• Comparative Analysis Across Species: Evolutionary conservation of VPS26 from yeast to humans, particularly in functionally critical regions like the VPS35-binding loop , highlights fundamental trafficking mechanisms. Researchers should leverage model organisms to understand conserved and divergent aspects of VPS26B function.

• Integration with Other Trafficking Machineries: Studies should explore how VPS26B-containing retromer complexes coordinate with other trafficking machineries like ESCRT, COPI/COPII, and clathrin systems. This includes temporal and spatial coordination, shared regulators, and potential crosstalk.

By integrating structural insights with cell biological approaches, and placing VPS26B within the broader context of cellular trafficking networks, researchers can develop more comprehensive models of membrane trafficking that better explain physiological functions and disease mechanisms related to protein transport.

What considerations should guide experimental design when studying VPS26B in disease models?

When investigating VPS26B in disease models, researchers should implement a strategic experimental approach that accounts for the protein's complex functions and interactions:

Experimental Design Framework:

• Model Selection Considerations:

  • Choose models that recapitulate relevant aspects of human pathology

  • Consider both cell-based and animal models to capture complexity

  • For neurodegenerative diseases, use models with appropriate aging components

  • Select models that allow differentiation between VPS26A and VPS26B functions

• Intervention Strategies:

  • Use conditional knockout approaches rather than constitutive deletion to avoid developmental confounders

  • Consider knockdown approaches with incomplete depletion to mimic partial loss of function

  • Implement rescue experiments with wild-type and mutant forms of VPS26B

  • Test mutations specifically in the VPS35-binding loop (residues 235-246) to disrupt retromer assembly

• Outcome Measurements:

  • Assess multiple trafficking pathways potentially affected by VPS26B dysfunction

  • Measure both biochemical markers (protein accumulation, missorting) and functional outcomes

  • Include longitudinal measurements to capture progressive changes

  • Quantify not just VPS26B levels but also its proper localization to endosomes

• Control Considerations:

  • Include VPS26A manipulations as comparative controls

  • Use mutations in the VPS35-binding loop as functional negative controls

  • Implement age-matched and gender-balanced controls for animal studies

  • Consider genetic background effects in animal models

• Translational Relevance:

  • Validate findings in human patient-derived samples when possible

  • Correlate experimental findings with human genetic data on VPS26B variants

  • Design interventions with potential therapeutic applications in mind